Overview
Establishing Multidisciplinary Clinical Pathways for Proactive, Individualized Treatment of Inflammatory Bowel Disease
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Despite advances and the availability of different therapies for the treatment of IBD, many patients never achieve or maintain remission and/or are dissatisfied with aspects of their therapy. Selecting, intensifying, sequencing, or combining therapies in IBD can be challenging for clinicians, especially considering the number of novel targeted therapies available and the expanding role of patient-reported outcomes in individualization of therapeutic decision-making. In addition, the care paradigm has evolved to include treat-to-target (T2T) strategies and, most recently, time-dependent treatment targets.
However, gastroenterologists report a myriad of barriers in adopting T2T strategies in routine clinical practice. Some are resource driven, with greater constraints in monitoring experienced by smaller clinical practices, but others are an absence of risk factors for patient stratification or prognostic criteria to inform treatment selection.
As the prevalence of IBD continues to increase, gastroenterology teams must continually assess and adapt to evolving therapeutic strategies to ensure proactive, targeted, and patient-centric treatment to improve outcomes. To support translation and implementation of the latest recommendations into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.
This activity is intended for gastroenterologists, gastroenterology-focused advanced practice providers, internists, clinical pharmacists, gastroenterology nurses, and other members of the multidisciplinary care team.
Current estimates show that up to 3.1 million people in the US have inflammatory bowel disease (IBD), which encompasses both Crohn’s disease (CD) and ulcerative colitis (UC), and that prevalence of IBD is increasing. IBD is associated with a wide range of GI symptoms (eg, abdominal pain, frequent bowel movement, and fecal urgency) that can be severe enough to require hospitalization in approximately 20% of patients, and 80% of patients also report extraintestinal manifestations of IBD and conditions related to malabsorption of food. In addition, IBD is a lifelong, uncurable condition with peak onset during early adulthood; consequently, patients with IBD experience significant disease burdens, suboptimal quality of life (QoL), reduced work productivity, and mental health impact over several decades of life.
Significant advances in the diagnosis and treatment of IBD have occurred over the past few decades. However, challenges remain in applying these developments in clinical practice, leading to continuing suboptimal outcomes. For example, diagnostic delays are common, with many patients consulting healthcare providers multiple times prior to diagnosis. When considering treatment, optimal management of IBD often necessitates the use of immunomodulator and/or biologic therapies. However, a significant proportion of patients with IBD continue to experience corticosteroid dependance, disease flares, and/or relapses, all of which negatively impact their health and QoL. In addition, even with the introduction of new therapies for IBD, the 5-year cumulative risk of surgery remains at 7% for patients with UC and 18% for patients with CD.
Considering the increasing prevalence of IBD, the significant impact of the disease on patients, and ongoing suboptimal patient outcomes, clinicians involved with the management of IBD need to remain current with recommended proactive treatment strategies, apply appropriate monitoring methods for assessing treatment response, and recognize the potential role of emerging biomarkers for precision medicine in the management of this devastating disease.
Upon completion of this activity, learners will be able to:
• Apply proactive treat-to-target strategies to facilitate management of IBD and improve patient outcomes
• Use and interpret available and emerging biomarkers in clinical practice to facilitate use of precision medicine in the management of IBD
• Evaluate efficacy and safety data of available and emerging therapies with differentiated mechanisms of action for the management of IBD
• Apply proactive treat-to-target strategies to facilitate management of IBD and improve patient outcomes
• Use and interpret available and emerging biomarkers in clinical practice to facilitate use of precision medicine in the management of IBD
• Evaluate efficacy and safety data of available and emerging therapies with differentiated mechanisms of action for the management of IBD
Unmet Needs in the Management of IBD
• Impact of IBD on patients
• Traditional treatment strategies and outcomes
• Impact of IBD on patients
• Traditional treatment strategies and outcomes
Proactive Treat-to-Target Strategies in the Management of IBD
• Current recommendations
• Short, medium, and long-term treatment targets
• Initial treatment selection
• Assessing treatment response
• Considerations for changing therapy
• Multidisciplinary care pathways
Emerging Biomarkers for Precision Medicine in IBD
• Emerging biomarkers
• Potential roles of emerging biomarkers in clinical practice
Emerging Therapies With Novel Mechanisms of Action in IBD
• Novel therapeutic targets and underlying rationale
• Emerging therapies
• Potential roles in clinical practice
Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Takeda Pharmaceuticals U.S.A., Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Chair
Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Co-Director, Digestive Diseases Center
Clinical Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Chicago, IL
Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Co-Director, Digestive Diseases Center
Clinical Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Chicago, IL
Faculty
David Choi, PharmD, BCACP
Clinical Pharmacy Specialist – Gastroenterology
Associate Director Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
As accredited providers by the ACCME, The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) ask everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
All of the relevant financial relationships listed for these individuals have been mitigated.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
The following financial relationships have been provided:
Russell D. Cohen, MD, FACG, AGAF (Chair)
Consulting/Advisory/Scientific Advisory Board: Abbvie Laboratories, Bausch Health, BMS/Celgene, Eli Lilly, Genetech, Gilead Sciences, Johnson & Johnson, Pfizer, Takeda
Data Safety Monitoring Board: Reistone BioPharma
Clinical Investigator/Grants(Principal Investigator; activity): Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast, Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Inc. Takada, UCB
The following financial relationships have been provided:
David Choi, PharmD, BCACP
Consulting Agreements: : Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceuticals, Pfizer
Speakers' Bureau: Abbvie, Eli Lilly, Janssen Pharmaceuticals
The University of Chicago Pritzker School of Medicine, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: azathioprine, methotrexate, mercaptopurine, systemic corticosteroids, brepocitinib, duvakitug, obefazimod, tulisokibart, zasocitinib, icotrokinra, PF-06480605, and ABBV-382 are not approved for the treatment of IBD.
To receive credit, learners are required to complete the assessment, view the content, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 3.00 contact hours.
ACPE Universal Activity Number: 0396-9999-25-001-H01-P
Activity Type: Application
Release Date: 6/13/2025
Expiration Date: 6/13/2026
CPE credit will be submitted to CPE Monitor® on the first business day of each month.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
